Moleculin Biotech
MBRX
20 hedge funds and large institutions have $4.44M invested in Moleculin Biotech in 2023 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 4 closing their positions.
380% more capital invested
Capital invested by funds: $925K → $4.44M (+$3.52M)
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
5% more funds holding
Funds holding: 19 → 20 (+1)
0.03% more ownership
Funds ownership: 0.02% → 0.05% (+0.03%)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$1.78M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$35.7K |
| 3 |
AWM
Atticus Wealth Management
Palm Beach Gardens,
Florida
|
+$27.6K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$11K |
| 5 |
Renaissance Technologies
New York
|
+$5.19K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sio Capital Management
New York
|
-$116K |
| 2 |
Millennium Management
New York
|
-$13K |
| 3 |
BlackRock
New York
|
-$3.94K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$3.94K |
| 5 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
-$2.7K |
MBRX Hedge Fund Activity: Q4 2023 in Review
20 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q4 2023, worth a combined $4.44M — up 380% from $925K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new MBRX positions and 4 closed out — a net gain of 1 holder — while 3 added to existing stakes and 4 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $1.78M. The largest seller was Sio Capital Management, exiting entirely with an estimated $116K sold.
- 20 institutional investors held Moleculin Biotech (MBRX) as of Q4 2023, up from 19 in Q3 2023.
- Funds reported $4.44M of Moleculin Biotech stock for Q4 2023, up 380% quarter-over-quarter.
- 5 funds opened new Moleculin Biotech positions in Q4 2023 and 4 closed out, a net change of +1 holder.
- The largest Moleculin Biotech buyer in Q4 2023 was Armistice Capital, an estimated $1.78M added.
- The largest Moleculin Biotech seller in Q4 2023 was Sio Capital Management, an estimated $116K sold.
Based on aggregated 13F filings for Q4 2023.